Klin Farmakol Farm. 2005;19(2):100-105

Visceral leishmaniasis treatment progress

Vladimír Mihál1, Dagmar Pospíšilová1, Martina Suková2, Jan Starý2
1 Dětská klinika LF UP a FN Olomouc
2 Klinika dětské hematologie a onkologie, UK 2. LF a FN Motol, Praha

Leishmaniasis, a parasitic disease transmitted by the suction of blood of some species of sandflies, affects various age groups depending on the infecting Leishmania species, geographic location, disease reservoir, and host immunocompetence. Visceral leishmaniasis is the most severe form of the disease which, if left untreated, could have a life-threatening course. The extent and presentation of the disease depend on several factors, including the humoral and cell-mediated immune response of the host, the virulence of the infecting species, and the parasite burden. Intermittent fever, splenomegaly, hepatomegaly, lymph node enlargement, thrombocytopaenia, rapid weight loss, anaemia, leukopaenia and hypergammaglobulinaemia are the most common findings of visceral leishmaniasis. The authors describe two cases of paediatric visceral leishmaniasis diagnosed in the Czech Republic. Both children were infected in Mediterranean countries several months before clinical presentation.

Keywords: Key words: visceral leishmaniasis, Leishmania infantum, Leishmania donovani, Mediterranean area, fever of unknown origin, splenomegaly, liposomal amphotericin B.

Published: January 1, 2006  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Mihál V, Pospíšilová D, Suková M, Starý J. Visceral leishmaniasis treatment progress. Klin Farmakol Farm. 2005;19(2):100-105.
Download citation

References

  1. Singh S, Sivakumar R. Challenges and new discoveries in the treatment of leshmaniasis. J Infect Chemother 2004; 10: 307-315. Go to original source... Go to PubMed...
  2. Sundar S, Sindermann H, Klaus J, et al. Oral miltefosine treatment in children with mild to moderate Indian visceral leishmanisis. Pediatr Infect Dis J 2003; 22: 434-438. Go to original source... Go to PubMed...
  3. Paris C, Loiseau PM, Bories C, et al. Miltefosine induces apoptosis-like death in Leishmania donovani promastigotes. Antimicrob Agents Chemother 2004; 48: 852-859. Go to original source... Go to PubMed...
  4. Sindermann H, Croft SL, Engel KR, et al. Miltefosine (Impavido): the first oral treatment against leishmaniasis. Med Microbiol Immunol (Berl) 2004; 193: 173-180. Go to original source... Go to PubMed...
  5. More B, Bhatt H, Kukreja V, Ainapure SS. Miltefosine: great expectations against visceral leishmaniasis. J Postgrad Med 2003; 49: 101-103. Go to original source... Go to PubMed...
  6. Kumar P, Pai K, Tripathi K, et al. Immunoblot anlysis of the immune response to Leishmania donovani polypeptides in case of human visceral leishmaniasis: its usfulness in prognosis. Clin Dian Lab Immunol 2002; 9: 1119-1123. Go to original source...
  7. Aguado JM, Lumbreras C, González-Vidal D, et al. Assessment of nephrotoxicity in patiens receiving amphotericin B lipid komplex: a pharmacosurveillance study in Spain. Clin Microbiol Infect 2004; 10: 785-790. Go to original source... Go to PubMed...
  8. Prasad R, Kumar R, Jaiswal BP, Singh UK. Miltefosine: An oral drug for visceral leishmaniasis. Indian J Pediatr 2004; 71: 143-144. Go to original source... Go to PubMed...
  9. Bhattacharya SK, Jha TK, Sundar S, et al. Efficacy and tolerability of miltefosine for childhood visceral leishmaniasis in India. Clin Infect Dis 2004; 38: 217-221. Go to original source... Go to PubMed...
  10. Bucheton B, Abel L, El-Safi S, et al. A major susceptibility locus on chromosome 22q12 plays a critical role in the control of Kala-Azar. Am J Hum Genet 2003; 73: 1052-1060. Go to original source... Go to PubMed...
  11. Lobovská A, Nohýnková E. New drugs for treatment of parasitic infections. Cas Lek Cesk 2003; 142: 177-181. Go to PubMed...
  12. Berman J. Current treatment approaches to leishmaniasis. Curr Opin Infect Dis 2003; 16: 397-401. Go to original source... Go to PubMed...
  13. Verma NK, Dey CS. Possible mechanism of miltefosine-mediated death of Leishmania donovani. Antimicrob Agents Chemother 2004; 48: 3010-3015. Go to original source... Go to PubMed...
  14. Dupouy-Camet J. New drugs for the treatment of human parasitic protozoa. Parassitologia 2004; 46: 81-84. Go to PubMed...
  15. Murray HW. Progress in the treatment of a neglected infectious disease: visceral leishmaniasis. Expert Rev Anti Infect Ther 2004; 2: 279-292. Go to original source... Go to PubMed...
  16. Rosenthal E, Marty P. Recent understanding in the treatment of visceral leishmaniasis. J Postgrad Med 2003; 49: 61-68. Go to original source... Go to PubMed...
  17. Croft SL, Seifert K, Duch?ne M. Antiprotozoal activities of phospholipid analogues. Mol Biochem Parasitol 2003; 126: 165-172. Go to original source... Go to PubMed...
  18. Harms G, Schönian G, Feldmeier H. Leishmaniasis in Germany. Emerg Infect Dis 2003; 9: 872-875. Go to original source... Go to PubMed...
  19. Seifert K, Matu S, Peréz-Victoria JP, et al. Characterization of Leishmania donovani promastigotes resistant to hexadecylphosphocholine (miltefosine). Int J Antimicrob Agents 2003; 22: 380-387. Go to original source... Go to PubMed...
  20. Davies CR, Kaye P, Drift SL, Sundar S. Leishmaniasis: new approaches to disease control. BMJ 2003; 326: 377-382. Go to original source... Go to PubMed...
  21. Murray HW. Treatment of visceral leishmaniasis in 2004. Am J Trop Med Hyg 2004; 71: 787-794. Go to original source...
  22. Cavalho L, Bacellar O, Brownell C, et al. Restoration of INF-? production and lymphocyte proliferation in visceral leishmaniasis. J Immunol 1994; 152:5949-5956. Go to original source...
  23. Bradley DJ, Tailor BA, Blackwell J, et al. Regulation of leishmania populations within the host. III. Mapping of the locus controlling susceptibility to visceral leishmaniasis in the mouse. Clin Exp Immunol 1979; 37: 7-14. Go to PubMed...
  24. Vidal S, Tremblay ML, Govoni G, et al. The Ity/Lsh/Bcg locus: natural resistence to infection with intracellular parasites is abrogated by disruption of the Nramp1 gene. J Exp Med 1995; 182: 655-666. Go to original source... Go to PubMed...
  25. Blackwell J, Freeman J, Bradley D. Influence of H-2 complex on acquired resistence to Leishmania donovani infection in mice. Nature 1980; 283: 72-74. Go to original source... Go to PubMed...
  26. Gama MEA, Costa JML, Pereira JCR, et al. Serum cytokine profile in the subclinical form of visceral leishmaniasis. Brazil J Med Biol Res 2004; 37: 129-136. Go to original source... Go to PubMed...
  27. Poljak V, Krč I, Ehrmann J. In: Manuál infekčních nemocí. Solen, 2000: 204-206.
  28. Smith O, Hann I, Cox C, et al. Visceral leishmaniasis: rapid response to Ambisone treatment. Arch Dis Child 1995; 73: 157-159. Go to original source... Go to PubMed...
  29. Mihál V, Gregůrková J, Michálková K, et al. Neobvyklá příčina horečky, splenomegalie a leukopenie. Pediat pro Prax 2001; 2: 83-84.
  30. Suková M, Starý J, Housková J, et al. Hemofagocytující lymfohistiocytóza jako manifestace viscerální leishmaniózy. Čas Lék čes 2002; 141: 581-584.
  31. Korbel DS, Finney C, Riley EM. Natural killer cells and innate immunity to protozoan pathogens. Int J Parasit 2004; 34: 1517-1528. Go to original source... Go to PubMed...
  32. Murray HW. Clinical and experimental advances in treatment of visceral leishmaniasis. Antimicrob Agenets Chemother 2001; 45: 2185-2197. Go to original source... Go to PubMed...
  33. Valenzuela JG, Belkaid Y, Garfield MK, et al. Toward a defined anti-Leishmania vaccine targeting vector antigens: characterization of a protective salivary protein. J Exp Med 2001; 194: 331-342. Go to original source... Go to PubMed...
  34. Reed SG. Leishmaniasis vaccination: targeting the source of infection. J Exp Med 2001; 194: F7-9. Go to original source... Go to PubMed...
  35. Brandonisio O, Spinelli R, Pepe M. Dendritic cells in leishmania infection. Microbes Infect 2004; 6: 1402-1409. Go to original source... Go to PubMed...
  36. Kuhlencord A, Maniera T, Eibl H, et al. Hexadecylphophocholine: oral treatment of visceral leishmaniasis in mice. Antimicrob Agents Chemother 1992; 36: 1630-1634. Go to original source... Go to PubMed...
  37. Bogdan C, Schönian G, Banuls AL, et al. Visceral leishmaniasis in a German child who had never entered a known endemic area: case report and review of the literature. Clin Infect Dis 2001; 32: 302-306. Go to original source... Go to PubMed...
  38. Naucke TJ, Pesson B. Presence of Phlebotomus (Transphlebotomus) mascitti Grassi,1908, (Dipter:Psychodidae) in Germany. Parasitol Res 2000; 86: 335-336. Go to original source... Go to PubMed...
  39. Ditis J, Ritsas I, Tsantali C, et al. Immune haemolytic anaemia due to visceral leishmaniasis in a young child. Eur J Pediatr 2003; 162: 49-50. Go to original source... Go to PubMed...
  40. Kollaritch H, Emminger W, Zaunschrim A, et al. Suspected autochthonous Kala-Azar in Austria. Lancet 1989; i: 901-902. Go to original source... Go to PubMed...
  41. Meinecke CK, Schottelius J, Oskam L, et al. Congenital transmission of visceral leishmaniasis (kala-azar) from an asymptomatic mother to her child. Pediatrics 1999; 104: E65. Go to original source... Go to PubMed...
  42. Chalupa P, Vaništa J, Burget I, et al. Přehled importovaných viscerálních leishmanióz v České republice. Bratisl Lek Listy 2001; 102: 84-91. Go to PubMed...
  43. Punda-Polic V, Sardelic S, Bradaric N. Visceral leishmaniasis in southern Croatia. Lancet 1998; 351: 188. Go to original source... Go to PubMed...
  44. MANDELL, DOUGLAS and BENNETT´S Principles and Practice of Infectious Diseases, 5th ed. Philadelphia, Churchill Livingstone 2000, 3263 pp.
  45. Herwaldt B. Leishmaniasis. Lancet 1999; 354: 1191-1199. Go to original source... Go to PubMed...




Clinical Pharmacology and Pharmacy

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.